EMBARK: Testosterone recovery to >250 ng/dL following treatment suspension.
Stephen J. Freedland, Ronald Tutrone, Fred Saad, Michael Cookson et autres
0 citationsJournal of Clinical Oncology
Daniel R. Saltzstein
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
136Publications signalées
3495Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentHormonal and reproductive studiesBladder and Urothelial Cancer TreatmentsRadiopharmaceutical Chemistry and Applications
Publications récentes
An intra-patient contemporaneous comparison of 18 F-piflufolastat and 18 F-flotufolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy.
B.R. Helfand, Jack R. Andrews, Phillip H. Kuo, Benjamin A. Gartrell et autres
0 citationsJournal of Clinical Oncology
An intra-patient contemporaneous comparison of 18F-piflufolastat and 18F-flotufolastat urinary radioactivity and pelvic region detection rates in men with low PSA biochemical recurrence of prostate cancer after radical prostatectomy
Luke T. Nordquist, Jack R. Andrews, Phillip H. Kuo, Benjamin A. Gartrell et autres
0 citationsEuropean Journal of Nuclear Medicine and Molecular Imaging
Abstract PR002: Development and validation of a semen-RNA based classifier for detection and risk stratification of prostate cancer
David jarrard, Duncan Whitney, Matthew Clay, D K Wylie et autres
0 citationsCancer Research
Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer With UGN-102: Outcomes From the 5-Year Long-Term Extension Study of the Single-Arm, Phase 2b Optima II Study
Neal D. Shore, Kent Chevli, Daniel R. Saltzstein, Yaron Ehrlich et autres
2 citationsClinical Genitourinary Cancer
Sasanlimab in combination with bacillus Calmette-Guérin (BCG) in BCG-naive in BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC): Patient-reported outcomes (PROs) from CREST.
Jens Bedke, Neal D. Shore, Thomas Powles, Matthew D. Galsky et autres
0 citationsJournal of Clinical Oncology
PD12-13 INTERIM ANALYSIS OF LIGHT-ACTIVATED TLD-1433 IN A PHASE II CLINICAL STUDY OF BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER CARCINOMA IN-SITU
Girish S. Kulkarni, Wassim Kassouf, Kyle A. Richards, Gautam Jayram et autres
2 citationsThe Journal of Urology
MP15-05 TREATMENT OF LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER WITH UGN-102: LONG-TERM OUTCOMES OF THE OPTIMA II STUDY
Neal D. Shore, Kent Chevli, Andrew Trainer, Daniel R. Saltzstein et autres
2 citationsThe Journal of Urology
MP13-01 COBRA: ASSESSMENT OF 64 CU-SAR-BISPSMA AND STANDARD OF CARE PROSTATE-SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY IN PATIENTS WITH BIOCHEMICAL RECURRENCE OF PROSTATE CANCER FOLLOWING DEFINITIVE THERAPY
Luke T. Nordquist, Eva Lengyelova, Daniel R. Saltzstein, David Josephson et autres
0 citationsThe Journal of Urology
PD04-12 SEMEN-BASED TRANSCRIPTOMIC BIOMARKERS FOR PROSTATE CANCER DETECTION
Duncan Whitney, Matthew R. Clay, Joel Wipperfurth, Mohsen Nabian et autres
0 citationsThe Journal of Urology
Intra-patient comparison of urinary radioactivity after 18 F-piflufolastat and 18 F-flotufolastat PET in men with low PSA biochemical recurrence of prostate cancer who have had radical prostatectomy.
Jack R. Andrews, David Josephson, Daniel R. Saltzstein, Andrei S. Purysko et autres
0 citationsJournal of Clinical Oncology
COBRA: Assessment of the efficacy of 64 Cu-SAR-bisPSMA using histopathology as reference standard in patients with biochemical recurrence of prostate cancer following definitive therapy.
Luke T. Nordquist, Eva Lengyelova, Daniel R. Saltzstein, David Josephson et autres
0 citationsJournal of Clinical Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.